TABLE 3

The effect of initial pulmonary arterial hypertension-specific dual oral combination therapy regimens on haemodynamic parameters at first follow-up visit

Treatment regimen	Patients n	Visit	mPAP mmHg	Cardiac index L·min⁻¹·m⁻²	PVR dyn·s·cm⁻⁵	Change in PVR from baseline dyn·s·cm⁻⁵	p-value^#
Bosentan+PDE5 inhibitor	78	Baseline	54.1±10.7	2.14±0.49	1040±376		0.74
Bosentan+PDE5 inhibitor	78	First follow-up^¶	46.0±11.1	3.17±0.82	579±273	−452±23 (−498– −407)
Ambrisentan+PDE5 inhibitor	19	Baseline	52.5±8.9	2.15±0.59	913±258
Ambrisentan+PDE5 inhibitor	19	First follow-up^¶	41.1±9.7	2.92±0.66	504±143	−470±46 (−561– −379)
Sildenafil+ERA	69	Baseline	55.3±10.3	2.18±0.53	1044±371		0.03
Sildenafil+ERA	69	First follow-up^¶	47.6±10.8	3.13±0.81	605±267	−427±24 (−474– −380)
Tadalafil+ERA	28	Baseline	50.0±9.6	2.06±0.47	945±323
Tadalafil+ERA	28	First follow-up^¶	38.8±8.8	3.09±0.75	465±188	−524±37 (−596– −451)

Data are presented as mean±sd or mean±sd (95% CI) unless otherwise stated. mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; PDE5: phosphodiesterase type 5; ERA: endothelin receptor antagonist. ^#: comparisons of combined bosentan and PDE5 inhibitor versus ambrisentan and PDE5 inhibitor, and combined sildenafil and ERA versus tadalafil and ERA (ANOVA adjusted for baseline values); ^¶: median follow-up time 4.1 months (interquartile range 3.5–4.9 months).